# SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy

> **NCT02945813** · PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 112 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Metformin
- **RADIATION:** Salvage Radiotherapy SRT

## Key facts

- **NCT ID:** NCT02945813
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-24
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 112 (ACTUAL)
- **Why stopped:** Trial was prematurely closed for accrual by the SAKK Board and the follow-up period shortened to one year after last RT fraction of the last patient
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945813, "SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02945813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*